{
  "schema_version": "blend_json_v1",
  "blend": {
    "slug": "glp1-sma",
    "display_name": "GLP-1 SMA",
    "status": "active",
    "taxonomy_keys": [
      "metabolic_weight_blend"
    ],
    "components": [
      "semaglutide"
    ],
    "components_unresolved": [
      "amylin"
    ],
    "sections": {
      "overview": [
        {
          "title": "What this product is",
          "text": "GLP-1 SMA is a supplier commercial name for semaglutide \u2014 the original GLP-1 receptor agonist in this class (Wegovy / Ozempic). It has the largest real-world dataset of any compound in the incretin category, with STEP trial data showing ~15% body weight reduction. The 'amylin' component listed by some suppliers is not a resolved component on this platform."
        }
      ],
      "claims": [],
      "safety": [
        {
          "text": "Pep-Talk curation pending: we\u2019re reviewing the evidence and will expand this section soon.",
          "evidence_refs": []
        }
      ],
      "use_cases": [
        {
          "title": "Use cases (real-world)",
          "text": "Use cases are framed as intent + context, not as a recommendation."
        },
        {
          "text": "People usually consider blends when they\u2019re trying to simplify decision-making, stack fewer vials, or chase a combined effect profile. The downside is more moving parts and more uncertainty."
        },
        {
          "text": "If one component would be a bad fit for you (meds, history, side effects), the blend is also a bad fit \u2014 even if the other component seems appealing."
        }
      ],
      "interaction_summary": [
        {
          "title": "Interaction summary",
          "text": "Interaction flags are category prompts \u2014 not dosing instructions."
        },
        {
          "text": "Blends inherit interaction risk from every component. If one component has a meaningful interaction class, treat the blend as having that interaction class."
        },
        {
          "text": "If you\u2019re on prescription meds (especially cardio, anticoagulant/antiplatelet, serotonergic, immunomodulating), treat uncertainty as a reason to slow down and verify with a clinician."
        }
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "GLP-1 SMA \u2014 reference index",
        "source_type": "website",
        "source_id": "https://pubmed.ncbi.nlm.nih.gov/?term=GLP-1+SMA",
        "evidence_grade": "mechanistic_only",
        "notes": "Index link for literature discovery. This file intentionally contains no protocol instructions."
      }
    ],
    "disclaimer": {
      "text": "This blend page is informational. It does not provide protocols or instructions. Claims must be supported by cited evidence.",
      "updated_at": "2026-01-19"
    },
    "meta": {
      "generated_from": "content/blends/_index.json",
      "generated_at": "2026-01-19"
    },
    "practical": {
      "bottom_line": "Pep-Talk curation pending: this practical summary will be expanded with real-world uses, common downsides, and red flags as evidence is reviewed.",
      "benefits": [],
      "common_downsides": [],
      "serious_red_flags": [],
      "who_should_be_cautious": [],
      "schema_version": "blend_practical_block_v1"
    },
    "intent_label": "GLP-1 receptor agonist",
    "rationale": "GLP-1 SMA is a supplier commercial name for semaglutide \u2014 the original GLP-1 receptor agonist in this class (Wegovy / Ozempic). It has the largest real-world dataset of any compound in the incretin category, with STEP trial data showing ~15% body weight reduction. The 'amylin' component listed by some suppliers is not a resolved component on this platform.",
    "synergy_note": null,
    "is_single_compound": true,
    "who_its_for": "Weight loss and metabolic health. See the individual compound profile for full details.",
    "component_roles": {
      "semaglutide": "GLP-1 receptor agonist \u2014 appetite suppression, gastric emptying, and blood sugar regulation via GLP-1 pathway"
    }
  }
}